Pasi Jänne, MD, PhD, is the Director of the Lower Center for Thoracic Oncology and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute, and a Professor of Medicine at Harvard Medical School. He is also the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute and Director of the ChenHuang Center for EGFR Mutant Cancers. Dr. Jänne’s research combines laboratory based studies, with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. Furthermore, he has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his work has led to the development of several clinical trials and new therapies for lung cancer patients.

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an associate professor of oncology for Johns Hopkins University School of Medicine.

Dr. Levy is a physician scientist who is interested in innovative immunotherapeutic approaches for advanced stage lung cancer patients and biomarkers that help define those patients more likely to respond to such agents. He has an expertise in thoracic malignancies, including non-small cell lung cancer, small cell lung cancer and thymic malignancies, as well as head and neck cancer.

Jyoti Patel is Professor of Medicine at the Northwestern University. She is the Director of Thoracic Oncology and oversees all lung cancer clinical and research activities. She has devoted her career to improving the lives of those with lung cancer. She has authored numerous publications and has served as the principal investigator of multiple clinical trials. She has been instrumental in developing clinical guidelines for the treatment of lung cancer. In addition, she is Associate Vice Chair of Clinical Research in the Department of Medicine. She has had leadership on national cancer committees including the National Comprehensive Cancer Network, Hoosier Oncology Group, and the Alliance for Clinical Trials in Oncology. She has served the American Society of Clinical Oncology (ASCO) in many educational and scientific capacities over the years.

Dr. Spira is a medical oncologist and is director of the Virginia Cancer Specialists Research Institute and the Phase I Trial Program, where he is actively involved in advancing medicine and offering targeted treatment options for patients. His research interests include immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is co-chair of the US Oncology thoracic oncology committee, chair of the US Oncology research executive committee, and member of the US Oncology national policy board executive committee. He also serves on the cancer research committee of the American Society for Clinical Oncology. He is a faculty member at Johns Hopkins School of Medicine and serves as assistant professor of oncology.

Dr. Helena A. Yu is a Thoracic Oncologist and Associate Attending who focuses her clinical care and research on lung cancer at the Memorial Sloan Kettering Cancer Center, in New York, USA. She also holds a position as an Associate Professor of Medicine at Weill Cornell Medical College in New York.